SciVision Biotech Inc
TWSE:1786
Intrinsic Value
SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. [ Read More ]
The intrinsic value of one
SciVision Biotech Inc
stock under the Base Case scenario is
121.77
TWD.
Compared to the current market price of 100.5 TWD,
SciVision Biotech Inc
is
Undervalued by 17%.
SciVision Biotech Inc's market capitalization is 6.8B TWD.
SciVision Biotech Inc stock price is 100.5 TWD.
SciVision Biotech Inc stock price (100.5 TWD) is 17% less than its Intrinsic Value (121.77 TWD).
SciVision Biotech Inc stock price (100.5 TWD) is 44% less than its DCF Value (180.46 TWD). Open DCF Valuation
SciVision Biotech Inc stock (63.07 TWD) is 37% less than its price (100.5 TWD). Open Relative Valuation
SciVision Biotech Inc has upside potential of 48% compared to the average analyst price target.
Open Wall St Estimates
SciVision Biotech Inc's ROE (Return on Equity) for the past 12 months is positive and is equal to 11%.
SciVision Biotech Inc's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 12%.
SciVision Biotech Inc has positive three-year average ROE (Return on Equity): 9%. The company is efficient at transforming stockholders' equity into net income.
SciVision Biotech Inc's ROE (Return on Equity) has increased in the last 3 years from 8% to 11%.
SciVision Biotech Inc's ROIC (Return on Invested Capital) has increased in the last 3 years from 8% to 12%.
SciVision Biotech Inc has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
SciVision Biotech Inc's Revenue has grown by an exceptional 28% over the past 12 months.
SciVision Biotech Inc's Revenue has been growing by 15% per year for the last 3 years.
SciVision Biotech Inc has positive Net Income for the last twelve months.
SciVision Biotech Inc has positive Operating Income for the last twelve months.
SciVision Biotech Inc has negative Net Debt. This means that the company has more cash and short-term investments (804m TWD) than debt (347m TWD).
SciVision Biotech Inc has positive Free Cash Flow for the last twelve months.
SciVision Biotech Inc has positive Gross Profit for the last twelve months.
SciVision Biotech Inc's D/E (Debt to Equity) is very low and is equal to 0.21.
SciVision Biotech Inc's short-term assets (1B TWD) exceed its short-term liabilties (145m TWD).
SciVision Biotech Inc's long-term assets (2B TWD) exceed its long-term liabilties (534m TWD).
SciVision Biotech Inc's Altman Z-Score is very high and is equal to 6.73.
SciVision Biotech Inc earns more than enough operating income (200m TWD) to safely cover interest payments on its debt (424k TWD).
Valuation Backtest
SciVision Biotech Inc
Run backtest to discover the historical profit from buying and selling
SciVision Biotech Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
SciVision Biotech Inc
Balance Sheet Decomposition
SciVision Biotech Inc
| Current Assets | 1B |
| Cash & Short-Term Investments | 804.1m |
| Receivables | 96.2m |
| Other Current Assets | 103.6m |
| Non-Current Assets | 1.2B |
| PP&E | 1.1B |
| Intangibles | 2.1m |
| Other Non-Current Assets | 18.7m |
| Current Liabilities | 145m |
| Accounts Payable | 6.7m |
| Other Current Liabilities | 138.2m |
| Non-Current Liabilities | 388.7m |
| Long-Term Debt | 346.7m |
| Other Non-Current Liabilities | 42m |
Earnings Waterfall
SciVision Biotech Inc
|
Revenue
|
713m
TWD
|
|
Cost of Revenue
|
-200.5m
TWD
|
|
Gross Profit
|
512.5m
TWD
|
|
Operating Expenses
|
-312.9m
TWD
|
|
Operating Income
|
199.6m
TWD
|
|
Other Expenses
|
-21.7m
TWD
|
|
Net Income
|
177.9m
TWD
|
Free Cash Flow Analysis
SciVision Biotech Inc
Profitability Score
Profitability Due Diligence
SciVision Biotech Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
SciVision Biotech Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
SciVision Biotech Inc's solvency score is 95/100. The higher the solvency score, the more solvent the company is.
Score
SciVision Biotech Inc's solvency score is 95/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
SciVision Biotech Inc
According to Wall Street analysts, the average 1-year price target for
SciVision Biotech Inc
is 148.92 TWD
with a low forecast of 147.46 TWD and a high forecast of 153.3 TWD.
Shareholder Return
Price
SciVision Biotech Inc
| Average Annual Return | -0.46% |
| Standard Deviation of Annual Returns | 18.03% |
| Max Drawdown | -51% |
| Market Capitalization | 6.8B TWD |
| Shares Outstanding | 67 731 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
SciVision Biotech Inc
Country
Industry
Market Cap
Dividend Yield
Description
SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.
Contact
IPO
Employees
Officers
The intrinsic value of one
SciVision Biotech Inc
stock under the Base Case scenario is
121.77
TWD.
Compared to the current market price of 100.5 TWD,
SciVision Biotech Inc
is
Undervalued by 17%.
You don't have any saved screeners yet
